Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

Methods and Findings

The study looked at female patients with metastatic TNBC. They had not had any previous treatment. Three different combinations of chemotherapy were assessed. Nab-paclitaxel + carboplatin (PC),  gemcitabine + carboplatin (GC), and nab-paclitaxel + gemcitabine (PG). 191 patients were randomly assigned one of the three treatments.

The study concluded that PC resulted in the longest progression-free survival (on average 8.3 months). GC was associated with an average of 6.0 months of progression free survival. Treatment with PG resulted in 5.5 months of progression free survival on average. PC also resulted in the longest overall survival, followed by GC, then PG.

The bottom line

Of the three types of treatment assessed, nab-paclitaxel + carboplatin (PC) resulted in the longest progression free survival, and overall survival. Nab-paclitaxel + gemcitabine (PG) resulted in the shortest progression free survival and overall survival.

The fine print

This was a small study with only 191 women involved. This may have affected the results.

What’s next?

The results of this study may be worth discussing with your oncologist when coming up with a treatment plan for chemotherapy.

Published By :

Annals of oncology : official journal of the European Society for Medical Oncology

Date :

Jun 06, 2018

Original Title :

nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.

click here to get personalized updates